Skip to content
zameds

Dolutegravir (Lutavir, Hetvir, Ravic)

Dolutegravir

Hetero Drugs South Africa (Pty) Ltd

Registration

Applicant
Hetero Drugs South Africa (Pty) Ltd
Registrations
3

Variants

ProductStrength and formRegistrationStatusScheduleLeaflets
Lutavir 50

EACH TABLET CONTAINS: DOLUTEGRAVIR SODIUM EQUIVALENT TO DOLUTEGRAVIR 50,0 mg

5052000152/20.2.8/0001RegisteredNot determinedNone
Hetvir 50

EACH TABLET CONTAINS: DOLUTEGRAVIR SODIUM EQUIVALENT TO DOLUTEGRAVIR 50,0 mg

50520002.00152/20.2.8/0002.001RegisteredNot determinedNone
Ravic 50

EACH TABLET CONTAINS: DOLUTEGRAVIR SODIUM EQUIVALENT TO DOLUTEGRAVIR 50,0 mg

50520003.00152/20.2.8/0003.001RegisteredNot determinedNone

Regulatory status

This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.

Listings for this ingredient that could not be applied to this product

  • S4: Dolutegravir

    Consolidated Schedules 06 July 2026, line 6100

  • S4: Lamivudine

    Consolidated Schedules 06 July 2026, line 6850

This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.

C20H19F2N3O5419.40 g/mol

(3S,7R)-N-[(2,4-Difluorophenyl)methyl]-11-hydroxy-7-methyl-9,12-dioxo-4-oxa-1,8-diazatricyclo[8.4.0.03,8]tetradeca-10,13-diene-13-carboxamide

Drag to rotate. Structure from PubChem CID 54726191.

SAHPRA documents

SAHPRA has not published a professional information or patient information leaflet for this product.

Background

Loading...
Loading Wikipedia summary

Research articles

Loading...
Loading PubMed articles